KN 5601 K
Alternative Names: Anti-CD19/BCMA CAR-NK Cells; KN-5601 KLatest Information Update: 11 Feb 2026
At a glance
- Originator Rui Therapeutics
- Class CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Autoimmune disorders
Most Recent Events
- 03 Dec 2025 Phase-0 for Autoimmune disorders (In children, In adults, In adolescents, Treatment-experienced) in China (Parenteral) (NCT07283315)